For the Inventor, By the Inventor

Enter assignee name

Faron Pharmaceuticals Oy

USPTO Granted Patents = 14

CIPO Patents = 27

EPO Patents = 13

Trademarks = 5

Forward Citations = 12

Loading Chart...

Loading Chart...

16 inventors (with patents filed for the assignee):

Markku Jalkanen (9 out of 16 patents)

Sirpa Jalkanen (8 out of 14 patents)

Mikael Maksimow (6 out of 6 patents)

4. Marko Salmi (6 out of 11 patents)

5. Marita Vainio (2 out of 2 patents)

6. Heikki Irjala (2 out of 2 patents)

7. Juho Jalkanen (2 out of 2 patents)

8. Maija-Leena Hollmén (1 out of 1 patent)

9. Miro Viitala (1 out of 1 patent)

10. Ilse Piippo (1 out of 1 patent)

11. Matti Karvonen (1 out of 5 patents)

12. Alexander Spicer (1 out of 1 patent)

13. Jami Mandelin (0 patent)

14. Reetta Virtakoivu (0 patent)

15. Felix Vaura (0 patent)

14 patents: Sort by Forward Citations

1. 12472235 - Treatment of diseases with sequential administration of an agent capable of up-regulating CD73 and glucocorticoids (2025-11-18),

2. 12371486 - Humanized anti clever-1 antibodies and their use (2025-07-29),

3. 11421279 - Method for determining patient's responsiveness to type 1 interferon treatment and use of type 1 interferon to treat patient having specified single nucleoide polymophism (2022-08-23),

4. 11046761 - Humanized anti clever-1 antibodies and their use (2021-06-29),

5. 10884000 - Method of monitoring the efficacy of the anti-clever-1 therapy in cancer (2021-01-05),

6. 10526607 - Cell and therapeutical and diagnostical methods based thereon (2020-01-07),

7. 10293030 - Lyophilised pharmaceutical formulation and its use (2019-05-21),

8. 10247730 - Method for determining acute respiratory distress syndrome (ARDS) related biomarkers, a method to monitor the development and treatment of ARDS in a patient (2019-04-02),

9. 8975081 - Biomarker for monitoring development of diseases and assessing the efficacy of therapies (2015-03-10),

10. 8722045 - Cell and therapeutical and diagnostical methods based thereon (2014-05-13),

11. 7910097 - Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) and uses thereof (2011-03-22),

12. 7727521 - Method of ameliorating multi-organ failure resulting from ischemic reperfusion injury (2010-06-01),

13. 7534423 - Method for inducing an elevated level of adenosine in an individual (2009-05-19),

14. 7354577 - Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) and uses thereof (2008-04-08),

Faron Pharmaceuticals Oy is a clinical stage biopharmaceutical company based in Finland. Their focus is on developing innovative treatments for acute organ traumas, cancer immunotherapy, and vascular leakages. Faron's lead product Traumakine® is in advanced clinical trials for multiple conditions. They are committed to improving patient outcomes and advancing medical science.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

14 Patents

#9 in Turku

#221 in Finland

#40,882 in the World

Faron Pharmaceuticals Oy

Forward Citations = 12

16 inventors:

Markku Jalkanen (9 out of 16 patents)

Sirpa Jalkanen (8 out of 14 patents)

Mikael Maksimow (6 out of 6 patents)

4. Marko Salmi (6 out of 11 patents)

5. Marita Vainio (2 out of 2 patents)

Please report any incorrect information to support@idiyas.com

Loading…